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Abstract
Tuberculosis (TB) is responsible for death of nearly two million people in the world annually. Upon infection, Mycobacterium
tuberculosis (Mtb) causes formation of granuloma where the pathogen goes into dormant state and can live for decades
before resuscitation to develop active disease when the immune system of the host is weakened and/or suppressed. In an
attempt to better understand host-pathogen interactions, several groups have been developing in vitro models of human
tuberculosis granuloma. However, to date, an in vitro granuloma model in which Mtb goes into dormancy and can
subsequently resuscitate under conditions that mimic weakening of the immune system has not been reported. We
describe the development of a biomimetic in vitro model of human tuberculosis granuloma using human primary
leukocytes, in which the Mtb exhibited characteristics of dormant mycobacteria as demonstrated by (1) loss of acid-fastness,
(2) accumulation of lipid bodies (3) development of rifampicin-tolerance and (4) gene expression changes. Further, when
these micro granulomas were treated with immunosuppressant anti-tumor necrosis factor-alpha monoclonal antibodies
(anti-TNFa mAbs), resuscitation of Mtb was observed as has been found in humans. In this human in vitro granuloma model
triacylglycerol synthase 1deletion mutant (Dtgs1) with impaired ability to accumulate triacylglycerides (TG), but not the
complemented mutant, could not go into dormancy. Deletion mutant of lipY, with compromised ability to mobilize the
stored TG, but not the complemented mutant, was unable to come out of dormancy upon treatment with anti-TNFa mAbs.
In conclusion, we have developed an in vitro human tuberculosis granuloma model that largely exhibits functional features
of dormancy and resuscitation observed in human tuberculosis.
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Introduction
Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb),
remains a major threat to the world population as one-third of the
world population is latently infected. Upon infection, only 5% of
people develop active TB, whereas majority of people carry
a lifelong latent infection. Mtb enters the host via aerosolization,
where it infects and activates macrophages and dendritic cells in
the lungs. The activated dendritic cells, present the processed
antigens to CD4 T cells [1]. These activated lymphocytes and
infected macrophages, in response to inflammatory cytokines and
chemokines, migrate to the site of infection where they can form
organized structures called granulomas in which Mtb goes into
a drug-resistant dormant state. In latent TB infection, humans can
harbor a small number of dormant Mtb bacilli that are likely
contained in microgranuloma. These organisms are viable but in
a dormant state.
Animal models have been used to study various aspects of
granuloma formation, dormancy and the host-pathogen interac-
tions. Mice is not the natural host of Mtb; granuloma in mice have
a different cellular organization than in humans [2,3]. Rabbit and
guinea-pig models also do not exhibit the full spectrum of the
human TB disease [4]. Even though non-human primate models
more closely resemble the various manifestations of human TB [5]
they are prohibitively expensive to maintain under BSL3
laboratory conditions.
Several groups have attempted to develop in vitro models of
granuloma [6–7]. For example, an in vitro granuloma model was
developed to study the molecular interactions between mycobac-
teria and human host cells using mycobacterial antigen coated
sepharose beads, or live mycobacteria, to induce granuloma
formation with human peripheral blood mononuclear cells
(PBMCs) [8–12]. The Mtb in this model was a good step towards
using culture methods to study TB, but did not exhibit features of
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dormancy. In a lipid-loaded macrophage model Mtb has been
shown to go into a dormant state [13]. However resuscitation has
not been demonstrated in any human cell system. When the host
immune system is weakened, it is well known that dormant Mtb
resuscitates leading to active TB. Experimental evidence has
revealed that tumor necrosis factor (TNFa) plays a major role in
host defense against Mtb in both the active and chronic phases of
infection, [14–18]. Data suggest that some TNF activity is
required to maintain the integrity of the granuloma and to
confine the TB pathogen [17,19]. An in vitro human granuloma
model in which Mtb goes into a drug-resistant dormant state and
resuscitates upon conditions that mimic immune suppression
provides an opportunity to study both mycobacterial dormancy
and potential resuscitation that may occur with immunosuppres-
sant therapies. Our aim was to develop a biomimetic model of
latent TB that could be used to accurately reflect both granuloma
dormancy and reactivation.
In this report we present an in vitro model of human TB
granuloma and demonstrate the development of Mtb dormancy in
the granuloma and resuscitation upon immune suppression caused
by anti-TNFa mAb treatment. We demonstrate that deletion of
tgs1 (Rv3130), that has been strongly implicated in the de-
velopment of dormancy, prevented Mtb from going into dormancy
and deletion of lipY (Rv3097c), thought to be involved in
mobilization of stored TG, prevented resuscitation caused by
anti-TNFa mAb treatment. Thus, the in vitro granuloma model
emulates many TB features observed in human patients.
Results
Infection of Human PBMCs Resulted in the Formation of
3D Granuloma
To replicate dormant TB in an in vitro model, we infected
human PBMCs placed in a collagen matrix with Mtb H37Rv and
incubated for 8 days. PBMCs tended to form microscopic
granulomas (micro-granuloma) at multiplicity of infection (MOI)
1:0.1, as observed from aggregation of lymphocytes surrounding
infected macrophages (Fig. 1A). Corresponding control uninfected
samples from the same donors did not form these aggregates
(Fig. 1B) indicating that aggregation forms in response to Mtb
infection. At a lower MOI of 1:0.05, microscopic granulomas
could not be observed; for MOI of 1:1or higher, the Mtb cells
tended to induce lysis of the host cells (data not shown). The
granuloma-like shape of the cell aggregates formed following Mtb
infection was confirmed by histology. Granuloma samples
exhibited aggregation of lymphocytes around the macrophages
(Fig. 1C). We also observed formation of multinucleated giant cells
(Fig. 1D, arrows show multinucleated cells) which are a recognized
characteristic of tuberculosis granuloma. [10]. To identify the
cellular components of the in vitro grown granuloma immunohis-
tochemical examination was performed using Fluorescent CD68
(macrophage marker) and CD3 (T cells-shown) mAbs. The micro
granulomas were positive for both CD68 and CD3 antibodies,
thus providing further evidence that the granulomas consisted of
both T cells and macrophages (Fig. 1E).
Mtb Infection Resulted in a Decrease in Macrophage and
CD4+ T Cell Number
It has been reported that TB causes CD4 lymphocytopenia and
is associated with normal numbers of CD8 T cells [20]. In order to
test whether our model manifests a similar response, we
determined the changes in expression of cellular markers on host
cells in response to low-dose Mtb infection by flow cytometric
analysis. At1 wk and 2 wk post-infection, host PBMC cells were
isolated, from infected and uninfected cultures and stained with
antibodies as described in methods. Flow cytometric analysis was
performed for CD4+ and CD8+ T cells, B cells and monocytic
populations as shown in Figure 2. While there was an increase in
CD4+3+ T cells in uninfected samples at 2 wks (55.9%65.2%)
compared to 1 wk (44.8%68%), the inverse was found for infected
samples. A decline in numbers of these cells was observed at longer
culture times (45.6%66.7% at 1 wk and 38.8%67.1% at 2 wk)
(Fig. 2A). The CD8+3+ T cell as well as CD19+3- B cell
population remained relatively unchanged between uninfected
and Mtb-infected samples and also between 1 wk and 2 wk
samples (Fig. 2B, 2C). CD4+25+ T cells, which are ascribed to
regulatory T cells, are known to be involved in immunity to Mtb.
Figure 2D shows the relative changes in CD4+25+ T cells for
infected and uninfected cultures. A three-fold increase was
observed in the regulatory CD4+25+ T cell population upon
Mtb infection at 2 wk compared to 1 wk (1.5%60.1% at 1 wk and
4.4%61.4% at 2 wk). The change in macrophage cell numbers is
shown in Fig. 2E. There was a large reduction in numbers of
CD14+CD11c+ macrophages at 2 wk (50.8%629.8%) compared
to 1 wk (87.6%60.8%) in response to Mtb infection. No decline in
macrophage numbers was observed in uninfected samples at 2 wk
compared to 1 wk.
Infection of Human PBMCs with Mtb Induces
Inflammatory Cytokines
It is known that Mtb strongly induces cytokine production
during infection [21]. To determine the cytokine/chemokine
secretion profile of host cells in response to Mtb infection, the
culture supernatants from 8–9 day granuloma samples were used
for cytokine/chemokine analysis using a multiplex cytokine assay.
IFN-c, TNFa, IL-12p40 (Fig. 3A) and IP-10 (Fig. 3B) were
induced by Mtb infection. IP-10 is induced via IFN-c and TNFa,
so it is not surprising to observe this chemokine along with IFN-c
and TNFa production.
Mtb within the Granuloma goes into a Dormant State
Auramine-O and nile red staining. Dormant mycobacteria
are known to exhibit loss of acid-fastness and accumulate lipid
bodies as they go into dormancy [22–27]. To test whether Mtb in
the in vitro granuloma manifests such a dormant phenotype,
granuloma sections and Mtb cells from 0 day and 8 day granuloma
were dual stained with Auramine-O (acid-fast staining of Mtb
where cells stain fluorescent green) and Nile Red (lipid-body
containing Mtb cells stain fluorescent red). When granuloma
sections were stained, Mtb cells could be observed residing within
the granulomas (Fig. 4A, lower left panel). After 8 days the host
cells were lysed and Mtb cells were obtained from the granulomas.
It was found that Mtb cells had accumulated lipid bodies as
indicated by positive Nile red staining (Fig. 4A, top right, lipid
bodies can be seen in the inset) when compared to day 0. At day
0 Mtb cells exhibit less Nile red but more Auramine-O stained
positive cells (Fig. 4A, top left). In vitro Mtb-infected granulomas at
day 8 had a higher percentage of red stained cells as compared to
day 0 Mtb samples (Fig. 4A, lower right panel).
Rifampicin resistance. Literatures on Mtb dormancy in-
dicates that Mtb goes into a dormant state in the granuloma in vivo
[28]. Rifampicin (Rif)-tolerance is a characteristic of dormant Mtb
[24,29–31]. Approximately 10% of the Mtb from day 8 granuloma
samples exhibit phenotypic Rif resistance, as compared to less than
0.5% in the day 0 culture (Fig. 4B). The development of this drug
resistance phenotype strengthens the conclusion that our in vitro
granuloma model accurately reflects TB granulomas in humans.
In Vitro Model for Mtb Dormancy and Resuscitation
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Figure 1. Infection of human PBMC withMycobacterium tuberculosis resulted in the formation of microscopic granulomas. (A) Infected
PBMCs, (B) uninfected PBMCs, (C) H & E staining showing micro granulomas, (D) H & E staining showing multinucleated giant cells. (E) Fluorescent
staining of granulomas sections with DAPI (nuclear stain), CD68 (macrophage marker-shown in red) and CD3 (T cells-shown in green) monoclonal
antibodies.
doi:10.1371/journal.pone.0053657.g001
Figure 2. Mtb infection resulted in a decrease in macrophage and CD4+ T cell number. Granuloma samples were harvested and host cells
were analyzed for expression of cellular markers by flow cytometry as described in methods. Graphs depict 1 wk and 2 wk post-infection profiles of
uninfected and infected granuloma samples for (A) CD4+3+ T cells, (B) CD8+3+ T cells, (C) CD19+ B cells, (D) CD4+25+ T cells, (E) CD14+11c+
macrophages. Data are represented as mean +/2 SEM from 3 experiments.* p,0.05 for CD4+25+ cells at 2 wk time point for 1:0.1 MOI-infected
group compared to the uninfected group.
doi:10.1371/journal.pone.0053657.g002
In Vitro Model for Mtb Dormancy and Resuscitation
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Treatment of Granulomas with Anti TNFa Monoclonal
Antibody Caused Reactivation of Latent Mtb
TNFa is known to be involved in the formation and
maintenance of the granuloma [17,19]. Neutralizing TNFa or
its activity tends to disrupt the granuloma structure in vivo allowing
Mtb to emerge from dormancy and develop active TB [14–
16,18,32,33]. We tested whether the Mtb cells in the in vitro
granuloma can be resuscitated by anti-TNFamonoclonal antibody
treatment. Once the microgranuloma structures were formed,
anti-TNF-a mAbs were added to the media to assess if
resuscitation could be observed in vitro. Resuscitation was
monitored via changes in dormancy phenotypes, namely-
Auramine-O and Nile red staining pattern, and Rif resistance
after 6 days of anti-TNFa mAb treatment. Granulomas treated
with a control IgG were used for comparison. Mtb cells from
granulomas treated with the control IgG showed that majority of
the cells remained positive for Nile red, and fewer were positive for
the Auramine-O stain (Fig. 5A) as expected. However, a great
majority of the Mtb cells from granulomas treated with anti-TNFa
mAbs were positive for the Auramine-O, (Fig. 5A). Mtb from
Figure 3. Infection of human PBMCs with Mtb induces inflammatory Cytokines. Supernatants from granuloma samples or control
uninfected samples were saved at 8-day post-infection and cytokine/chemokine profile determined by multiplex cytokine analysis as described in
methods. Profiles for prominent cytokines and chemokine IL-1a, IL-12p40, IFN-c, RANTES and TNFa are shown in Figure 3A, whereas Cytokines and
chemokines IL-1b, IL-8, IL-6, MCP-1, IP-10, MIP-1a are shown in Figure 3B. Data are represented as mean +/2 SEM from 3 experiments.
doi:10.1371/journal.pone.0053657.g003
Figure 4. Mtb within the granuloma goes into a dormant state. (A) Auramine-O and Nile red staining of granuloma sections shows Nile Red
positive Mtb cells within the granuloma (figure 4A lower left panel, insert in 4A shows lipid bodies). The number of Auramine-O and Nile red positive
Mtb cells were counted from multiple fields, and percentage of Auramine-O (green) and Nile red (red) positive Mtb cells are presented graphically
(Figure 4A lower right panel) (B) Mtb from 8 day granuloma was resistant to Rif when compared to 0 day in vitro grown Mtb. Data are represented as
mean +/2 SEM from 3 experiments. P values were calculated using students t test. * p,0.05 for Rif resistance of Mtb from 8day granuloma compared
to Mtb from 0day in vitro grown Mtb.
doi:10.1371/journal.pone.0053657.g004
In Vitro Model for Mtb Dormancy and Resuscitation
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granulomas treated with anti-TNFa mAbs also exhibit significant-
ly less Rif tolerance than Mtb from granuloma treated with the
control IgG. (Fig. 5C).
Metabolic activity of Mtb. Alamar blue is a cell viability
indicator that uses the natural reducing power of living cells to
convert resazurin to bright red fluorescent molecule, resorufin,
thereby generating a quantitative measure of metabolic activity.
Mtb obtained from granulomas treated with the anti-TNFa mAbs
were more metabolically active as compared to Mtb from
granulomas treated with the control IgG (Fig. 5B) consistent with
reactivation of the granuloma.
Since fatty acids are thought to be the main source of energy, we
tested for the rate of catabolism of oleic acid and palmitic acid by
Mtb from granulomas treated with the control IgG or anti-TNFa
mAbs. As indicated by the amount of 14CO2 released from [1-
14C]
labeled oleic and palmitic acid, we found that the Mtb from
granulomas treated with anti-TNFa mAbs catabolized oleic and
palmitic acid at a higher rate (Fig. 5D) as compared to the Mtb
from granulomas treated with the control IgG.
Apoptosis Assay
It has been shown that mycobacterium tuberculosis infection
leads to apoptosis of macrophages and is mediated by TNFa [34].
In order to determine if Mtb caused apoptosis, PBMCs were
infected with Mtb H37Rv and apoptosis was determined in
uninfected PBMCs and after treatment of granulomas with IgG
and anti-TNFa mAb. DNA cleavage in apoptotic cells were
detected in situ in fixed cells utilizing terminal deoxynucleotidyl
transferase (TdT) by TUNEL assay. As assayed by the TUNEL
method, infection of Mtb resulted in apoptosis of human PBMCs,
however treatment of granulomas with anti-TNFa mAb, did not
result in any change in the number of apoptotic cells when
compared with granulomas treated with control IgG (figure 5E).
Effect of Anti-TNFa mAb Treatment on Changes in Gene
Expression Relevant to Dormancy and Resuscitation
Mtb cells recovered from in vitro granuloma showed dormancy
related phenotypes. When the Mtb cells within the in vitro
granuloma were treated with anti-TNFa mAb it demonstrated
resuscitation of Mtb cells from the in vitro dormant state [IgG
treated]. To determine whether the observed dormancy and
resuscitation related phenotypes are reflected in gene expression
changes, we examined the transcript levels of a few selected genes
that are mainly involved in storage lipid synthesis, lipid utilization,
catabolism, energy generation and transcription based on our
previous studies and other reports [13,35,36]. Transcript levels of
the tgs1, lipY, icl (isocitrate lyase), dosR, hspX and gltA1 (citrate
synthase I of TCA cycle; Rv1131) were significantly up regulated
Figure 5. Addition of anti-TNF a monoclonal antibody caused reactivation of dormant Mtb. (A) Auramine-O and Nile red staining of WT
Mtb from IgG and anti-TNF a antibody treated granulomas. (B) Alamar Blue readouts at different time intervals when WT Mtb cells from granulomas
treated with anti-TNF-a antibody or control IgG, were incubated with Alamar blue dye. (data of one representative data set has been displayed.) (C)
WT Mtb cells from granulomas treated with anti-TNF-a antibody had a lower antibiotic resistance as compared to WT Mtb cells from control IgG
treated granulomas. (D) Mtb cells from granulomas treated with anti-TNF a antibody catabolized fatty acids at a higher rate than Mtb from control
IgG treated granuloma. P values were calculated using students t test. p,0.05 for metabolism of oleic and palmitic acid for Mtb from anti-TNF-
aantibody treated granuloma compared to Mtb from IgG treated granuloma. (E) Infection of hPBMCs resulted in Apoptosis of these cells. Data are
presented as mean +/2 SEM from 3 experiments. P values were calculated using students t test. * p,0.05.
doi:10.1371/journal.pone.0053657.g005
In Vitro Model for Mtb Dormancy and Resuscitation
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in the dormant Mtb cells (IgG treated cells). lipY transcript level
was up regulated after anti-TNFa mAb treatment as might be
expected from its postulated role in lipid utilization required for
resuscitation. The citA (citrate synthase II; Rv0889c) and rpfA,
rpfB and rpfC [resuscitation-promoting factor genes A (Rv0867c),
B (Rv1009) and C (Rv1884c)] were up regulated at a lower level.
In the IgG treated cells rpoA and rpoB (RNA polymerase genes;
Rv3457c and Rv0667, respectively); atpA and atpB (ATP synthase
genes; Rv1308, Rv1304 respectively); nuoA, nuoB and nuoE (NADH
dehydrogenase I subunit genes; Rv3145, Rv3146 and Rv3149
respectively) were found to be down-regulated under dormancy
inducing condition (IgG treated) but up regulated under re-
suscitation inducing condition (anti-TNFa mAb treated) Fig. 6.
tgs1 Deletion Compromised the Ability of Mtb to go into
a Dormant State in the in vitro Human Granuloma Model
If Mtb utilizes fatty acids as a major source of energy as reported
[13,37], and if tgs1, that is known to be the primary contributor to
TAG synthesis, is involved, then deletion of tgs1 (Dtgs1), should
compromise the ability of the mutant to go into dormancy in the
in vitro granuloma model. To test for this possibility PBMCs from
human donors were infected with Mtb WT Dtgs1 mutant and
Dtgs1complemented strain (Dtgs1 C+) in a collagen matrix. WT
and Dtgs1 mutant and Dtgs1 C+ formed micro-granulomas. The
granulomas were then treated with either the control IgG or anti-
TNFa mAbs for 6 days, and Mtb cells were obtained from the
granulomas and assessed for dormancy.
Auramine-O and Nile red staining of WT Mtb cells from
granulomas treated with the control IgG, showed that most of the
cells remained positive for Nile red and that most of the WT Mtb
cells from granulomas treated with anti-TNFa mAb were positive
for the Auramine-O stain (Fig 7A). Were as staining of Dtgs1 Mtb
cells from granulomas treated with IgG, as well as those from
granulomas treated with anti-TNFa mAb showed that most of the
cells were positive for Auramine-O (Fig. 7A), indicating that the
Dtgs1 mutant Mtb cells accumulated less lipids as compared to WT
Mtb. Staining of Dtgs1 C+ Mtb cells showed that most of the Dtgs1
C+ Mtb cells from granulomas treated with anti-TNFa mAb were
positive for the Auramine-O stain indicating resuscitation, whereas
most of the cells from granulomas treated with the control IgG,
remained positive for Nile red indicating dormancy.
Alamar blue assay results suggest that WT Mtb cells obtained
from granulomas treated with anti-TNFa mAb and Dtgs1 mutant
Mtb cells from granulomas treated with IgG or anti-TNFa
antibody were more metabolically active as compared to WT
Mtb from granulomas treated with control IgG (Fig 7B).
WT Mtb from granulomas treated with IgG had a higher
percentage of Rif resistance as compared to the WT Mtb from
granulomas treated with anti-TNFa mAbs as well as Dtgs1 mutant
Mtb cells from granulomas treated with either IgG or anti-TNFa
mAb (Fig 7C). Dtgs1 C+ Mtb from granulomas treated with anti-
TNFa mAbs had a lower Rif resistance as compared to Dtgs1 C+
Mtb from granulomas treated with control IgG. All of these results
strongly suggest that tgs1 deletion compromised the ability of the
pathogen to go into dormancy.
Deletion of lipY Compromised the Ability of Mtb within
the in vitro Granuloma to Come out of Dormancy upon
Treatment with Anti TNF-a mAb
When the bacterium resuscitates, it utilizes the stored TG as its
energy source [38]. It is thought that lipY is involved in
hydrolyzing stored TAG as the pathogen emerges from dormancy.
It has been reported that lipY-disrupted mutant (D-lipY) loses its
ability to utilize stored TG. [36]. If Mtb utilizes lipY to mobilize
stored TG to break dormancy and resuscitate, anti-TNF-
a antibody treatment, should inhibit DlipY to resuscitate. To test
for this possibility PBMCs from human donors were infected with
MtbWT, DlipYmutant, or DlipY complemented strain (DlipY C+) in
the in vitro model. WT, DlipY mutant and the DlipY C+ formed
micro-granulomas. The granulomas were then treated with either
Figure 6. Gene expression profile of Mtb cells from in vitro granuloma treated with IgG anti-TNFa-mAb. Relative gene expression values
(fold changes of day 0) in IgG and anti-TNFa mAb treated Mtb cells are represented for a selected set of genes that are known to be involved in
dormancy and resuscitation conditions. Real-time Taqman RT-PCR measurement was performed to measure relative abundance of transcripts.
Relative quantitation method (ddCt) was used to determine the fold change in transcripts level. Gene transcript level is expressed as fold change in
log2 scale relative to the sample from in vitro grown starter culture used for infection of PBMC. Samples of starter culture (day 0) was used as
calibrator and 16S rRNA gene was used as the endogenous control to normalize the expression values. tgs1, triacylglycerol synthase1; lipY, lipase Y;
icl, isocitrate lyase; hspX, heat-shock protein X; dosR, dormancy response regulator; gltA1, citrate synthase 1; citA, citrate synthase II; rpf, resuscitation
promoting factor (A, B, and C); rpo, RNA polymerase (A and B); atp, ATP synthase (A and B subunits); nuo, NADH dehydrogenase (A, B and E subunits).
doi:10.1371/journal.pone.0053657.g006
In Vitro Model for Mtb Dormancy and Resuscitation
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the control IgG or anti-TNFa mAbs for 6 days, andMtb cells were
obtained from the granulomas and assessed for dormancy.
Auramine-O and Nile red staining of WT Mtb cells from
granulomas treated with the control IgG, showed that majority of
the cells were positive for Nile red and that most of the WT Mtb
cells from granulomas treated with anti-TNFa mAb were positive
for the Auramine-O stain (Fig 8A). Staining of DlipY mutant Mtb
cells from granulomas treated with IgG, as well as those from
granulomas treated with anti-TNFa mAb showed that most of the
cells remained positive for Nile red (Fig. 8A), suggesting that the
DlipY mutant Mtb cells could not break dormancy and reactivate,
unlike the WT Mtb. Staining of DlipY C+Mtb cells from
granulomas treated with anti-TNFa mAb, showed that majority
of the cells were positive for the Auramine-O stain, and that most
of the DlipY C+Mtb cells from granulomas treated with control
IgG, were positive for Nile red, as observed with the WT Mtb cells.
Alamar blue assays suggest that WT Mtb cells obtained from
granulomas treated with control IgG and DlipY mutant Mtb cells
from granulomas treated with IgG or anti-TNFa mAb were less
metabolically active as compared to WT Mtb from granulomas
treated with anti-TNFa mAb (Fig 8B), suggesting that deletion of
lipY compromised the ability of the pathogen to come out of
dormancy. DlipY C+Mtb cells from granulomas treated with anti-
TNFa mAb were more active as compared to the DlipY C+Mtb
cells from granulomas treated with control IgG, although the
complementation of DlipY gene resulted in less increase in
metabolic activity as compared to WT after treatment of
granulomas with anti-TNFa mAb.
WT Mtb from granulomas treated with IgG and DlipY mutant
Mtb cells from granulomas treated with IgG or anti-TNFa mAb
had a higher percentage of Rif resistance as compared to the WT
Mtb from granulomas treated with anti-TNFa mAb (Fig 8C),
suggesting that DlipY mutant had a compromised ability to come
out of dormancy. DlipY C+Mtb cells from granulomas treated with
anti-TNFa mAb had a lower percentage of Rif resistance as
compared to the DlipY C+Mtb cells from granulomas treated with
control IgG, although the difference in percentage of Rif resistance
of the DlipY C+Mtb cells from granulomas treated with control IgG
and anti-TNFa mAb, was less as compared to the difference in the
percentage of Rif resistance of the WT Mtb cells from granulomas
treated with control IgG and anti-TNFa mAb. This suggests that
the complementation of the lipY gene helped the mutant to regain
its ability to resuscitate upon treatment with anti-TNFa mAb.
However the resuscitation in the complemented strain was less
when compared to the WT Mtb cells.
Discussion
We report here, the development of an in vitro model of human
tuberculosis granuloma that mimics in vivo human granuloma.
Figure 7. tgs1 deletion compromised the ability of the Mtb to go into a dormant state. (A) Auramine-O and Nile red staining of WT and D-
tgs1 mutant and D-tgs1 complemented strain (D-tgs1C+) population in in vitro granuloma. (B) Alamar Blue readouts at different time intervals when
WT and D-tgs1 mutant and D-tgs1 complemented strain from granulomas treated with anti-TNF-a antibody or IgG, were incubated with Alamar blue
dye. (data of one representative data set has been displayed.) (C) D-tgs1mutant from granulomas treated with IgG or anti-TNF-a antibody had a lower
antibiotic resistance as compared to WT Mtb cells from IgG treated granulomas. Data are presented as mean +/2 SEM from 3 experiments. P values
were calculated using students t test. *p,0.05.
doi:10.1371/journal.pone.0053657.g007
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Several in vitro granuloma models have been developed in the past,
mainly using mycobacteria or mycobacterial antigen-coated beads
[8,39] but they do not truly recapitulate the dormant nature of the
mycobacterium within the human TB granuloma.
Dormancy ofMtb has been shown to be characterized by a non-
replicating state, development of resistance to antibiotic rifampicin
[30], loss of acid-fastness and accumulation of lipid bodies
[23,25,40]. Most in vitro models of Mtb dormancy are able to
induce non-replicating state in mycobacteria but they have not
been able to demonstrate all the above characteristics of dormant
mycobacteria. Recently, Deb et. al. developed a multiple stress
model of Mtb dormancy in an attempt to replicate the conditions
the pathogen is thought to encounter in host granuloma, and
showed that Mtb indeed exhibited dormancy as characterized by
all the hallmark characteristics of dormancy [36], however this
model does not involve host-pathogen interaction. In lipid loaded
THP-1 derived macrophages Mtb has been found to go into
a dormant state [13]. At low dose infection, which closely mimics
the in vivo scenario, Mtb in our granuloma model displays
characteristics of dormant Mtb, via. development of Rif-tolerance,
loss of acid fastness and accumulation of lipids bodies (Fig 4).
These results demonstrate development of Mtb latency in our
human granuloma model.
The present in vitro model and in vivo observations in human TB
share the following features: granuloma formation, multinucleated
giant cell formation, decrease in CD4 T cell counts, unchanged
CD8 T cell values, increase in CD4+CD25+ T cells, decrease in
activated macrophage cells, increase in cytokine and chemokine
secretion by host immune cells in response to Mtb infection,
Rifampicin-tolerance, loss of acid fastness and accumulation of
lipid bodies, and resuscitation upon immunosuppression by
treatment with anti-TNFa mAbs. Below we list features of our
in vitro model that are consistent with human findings.
Microstructure
In our model within 5–8 days post-infection, the lymphocytes in
human PBMCs show clustering around infected macrophages
resembling micro-granuloma aggregates (Fig 1). The micro-
granuloma is formed specifically in response to Mtb infection
since uninfected samples do not exhibit such aggregates. This
model can potentially provide insights into host-pathogen inter-
actions at various stages of human TB granuloma formation which
has not been possible with animal models as well as other in vitro
Figure 8. Deletion of lipY compromised the ability of Mtb to reactivate upon treatment with anti-TNFa mAb. (A) Auramine-O and Nile
red staining of WT and D-lip Y mutant and D-lip Y complemented strain (D-lip Y C+) population in in vitro grown granuloma. (B) Alamar Blue readouts
at different time intervals when WT and D-lip Y, and D-lip Y C+ Mtb cells from granulomas treated with anti-TNF-a antibody or control IgG, were
incubated with Alamar blue dye. (data of one representative data set has been displayed.) (C) D-lip Y mutant from granulomas treated with IgG or
anti-TNF-a antibody had a higher antibiotic resistance as compared to WT Mtb cells from anti-TNF-a antibody treated granulomas. Data are presented
as mean +/2 SEM from 3 experiments. P values were calculated using students t test. *p,0.05.
doi:10.1371/journal.pone.0053657.g008
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models. Multinucleated giant cell formation due to fusion of
macrophage cells is a characteristic of TB granuloma [8,41] and
our in vitro model is able to recapitulate this as observed from the
histological sections of the granuloma samples (Fig 1D). Impor-
tance of multinucleated giant cell in granuloma and their role can
be studied in detail using this model.
Cellular Responses
The pattern of cell surface marker expression on lymphocytes
from the in vitro granuloma model reflects data reported on
tuberculosis patients reported in literature [42,43]. The CD4 T
cells were significantly lower in the blood, but CD8 T cells were
normal in patients with pulmonary TB when compared with
values obtained in normal blood donors. [44] It is reported that
TB causes CD4 T cell lymphocytopenia and is associated with
normal numbers of CD8 T cells. In our in vitro granuloma model,
we also observed a similar decline in CD4 T cells while the CD8 T
cells and also B cells remain unchanged in the granuloma samples
(Fig 2). CD4+25+ regulatory T cells are known to be important in
host immune response to TB. There’s reportedly a three-fold
increase in the frequency of CD4+CD25 high T cells in blood and
disease sites in TB patients [45]. Similarly, we observed several-
fold increase in numbers of CD4+25+ regulatory T cells in
infected samples compared to uninfected culture samples (Fig 2). It
has been reported that there is a decrease in alveolar macrophage
numbers in bronchoalveolar lavage fluid obtained from affected
regions of pulmonary TB patients compared to non-affected
regions of the lungs of patients with active or inactive pulmonary
TB [46]. In our flow-cytometric profile of macrophage cells, we
also observed a large decrease in macrophage cell numbers and in
activated macrophages from the granuloma samples compared to
uninfected samples. Macrophages are the primary host cells for
Mtb and consequently, there is extensive cell death among this
population of cells.
Cytokine Responses
Several cytokines are known to play an important role in anti-
TB immunity. Increased mRNA expression of IFN-c TNF-a, IL-
6, IL-8 and IL-12 in tuberculosis granuloma [47] and secretion of
cytokines IL-1b, TNF-a and IL-6 in bronchoalveolar lavage fluid
from involved sites of pulmonary TB have been reported [48]. In
this in vitro model, we also observed induction of IFN-c, TNFa, IL-
12p40 and IP-10, in infected samples. Thus, our in vitro model is
able to faithfully recapitulate the in vivo scenario in terms of
cytokine and chemokine secretion by host immune cells in
response to Mtb infection.
Dormancy
Mtb is thought to survive in a dormant state for many years in
the host. Under opportune conditions, like immunosuppression or
co-infection with infectious agents like HIV, Mtb resuscitates to
develop active TB. There are widely reported cases of reactivation
of latent TB as a result of anti-arthritis treatments based on
neutralization of TNF-a or its receptor, eg. Adalimumab,
Etanercept or Infliximab. [49,50] TNF-a is important in de-
velopment and maintenance of TB granuloma, and is essential for
maintaining the state of dormancy [32,51,52] [50,53–56].
Neutralizing TNF-a or its activity allows Mtb to emerge from
dormancy and develop active TB [14–16,18,32,33]. Although we
did not find any significant difference in the structural morphology
of the granulomas treated with a control IgG and anti-TNFa
monoclonal antibody, we did find differences in the state of
dormancy of the Mtb from these granulomas. This is in agreement
with non-human primate studies in which it was demonstrated
that TNF neutralization reactivates latent infection, but retained
normal granuloma structure, despite TNF neutralization during
both primary and latent infection [57]. Recently, zebrafish and
nonhuman primate models reported that although TNF is
important for overcoming acute infection and preventing reactiva-
tion, the overall granuloma formation is normal in the absence of
TNFa [53,57,58].
Reactivation
It is known that the dormant Mtb within the granulomas is in
a metabolically inactive state. Under certain conditions, such as
treatment with anti-arthritis drugs e.g. Adalimumab, Etanercept
or Infliximab, that are based on neutralization of TNF-a or its
receptor, the dormant Mtb becomes metabolically active, resulting
in active TB. In our in vitro model, resuscitation of the dormant
Mtb following treatment of granulomas with anti-TNFa mAb was
demonstrated by the Alamar Blue assay data, which showed an
increase in metabolic activity of the Mtb from anti-TNFa mAb
treated granulomas. Furthermore, increased utilization of oleic
and palmitic acid by the Mtb from anti-TNFa mAb treated
granulomas as compared to that of the Mtb from the control IgG
treated granulomas also demonstrate that the Mtb is metabolically
active following anti-TNFa monoclonal antibody treatment. Rif
tolerance and Auramine-O and Nile red staining data also suggest
resuscitation of theMtb following anti-TNFa monoclonal antibody
treatment. No other in vitro model has demonstrated resuscitation
of Mtb under immunosuppressive conditions.
Apoptosis
It has been reported that Mtb infection causes apoptosis of
monocytes [59,60]. Our TUNEL assay results also show that
infection of PBMC cells with Mtb resulted in apoptosis of these
cells in our in vitro granuloma model. However anti-TNF mAb
treatment did not affect apoptosis. Our data correlates to the study
that showed that neutralization of secreted TNF-a did not inhibit
Mtb-induced apoptosis in PBMC from TB-patients [61]. SinceMtb
-induced apoptosis in is not mediated by the production of TNF-
a [61], in our in vitro granuloma model, we did not observe any
change in the number of apoptotic cells following treatment of
granulomas with anti-TNF mAb.
Gene Expression Profile
To determine whether the dormancy and resuscitation
phenotypes observed with the Mtb cells from in vitro granuloma
are reflected in the change in gene expression levels, we measured
transcript levels of certain selected genes associated with TG
accumulation and catabolism, dormancy and resuscitation. The
Mtb genes, tgs1, gltA1, citA, icl, hspX and dosR, that are known to be
up regulated under dormancy inducing conditions [13,35,36] were
more highly induced in IgG treated Mtb cells, compared to anti-
TNFa-mAb treated Mtb cells from the in vitro granuloma. This
result is consistent with the observed dormancy phenotypes in Mtb
cells from in vitro granuloma. Down-regulation of these genes and
up regulation of lipY in anti-TNFa-mAb treated Mtb cells from
granuloma indicate that the Mtb cells were under resuscitation
state. We previously have shown that lipY transcript level goes up
when the Mtb cells are starved after lipid accumulation under
dormancy inducing stress conditions [62]. The up regulation of
genes that are involved in resuscitation (rpfA, rpfB and rpfC), energy
generation (nuoA, nuoB, nuoE, atpA, atpB) and transcription (rpoA,
rpoB) strongly suggest thatMtb cells inside the granuloma that were
dormant prior to the treatment with anti-TNFa-mAb were
resuscitated by anti-TNFa-mAb treatment. Thus, this in vitro
granuloma model using human PBMC is suitable for studying
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dormancy and resuscitation, mimicking the events that are
thought to happen when a person with latent Mtb infection is
subjected to immunocompromising conditions.
Mtb Mutants
The conclusion that in our in vitro granuloma model mimics
what happens in vivo is supported by studies on Mtb mutants. tgs1
is known to be involved in lipid accumulation that occur in Mtb
under different stresses that lead to dormancy [13,63]. Earlier
studies from our lab have shown that the tgs 1 deletion mutant,
with impaired ability to accumulate TG, exhibited a lesser degree
of antibiotic tolerance. [36]. In our in vitro granuloma model tgs1
deletion mutant showed compromised ability to go into dormancy
There is evidence that lipY, the only known mycobacterial enzyme
with long chain TG hydrolase activity, is involved in the utilization
of stored TG in Mtb [62,64]. It has been suggested that lipY is
involved in mobilizing stored TG during reactivation. In our
human granuloma model the lipY deficient Mtb demonstrated
compromised ability to resuscitate upon immunosuppression with
anti-TNFa antibody.
Thus, we believe that the battery of phenotypic and functional
assays demonstrate that we have been able to develop an in vitro
granuloma model of dormancy and resuscitation that accurately
reflects human responses. Our granuloma model is able to mimic
human micro-granuloma in terms of cellular organization,
expression of cellular markers on host cells and development of
mycobacterial dormancy. The compromised ability of the tgs 1
mutant to go into dormancy and the inability of lipY mutant to get
out of dormancy add further validation to the conclusion that the
present model mimics the in vivo situation. The most important
application of this in vitro model may be to provide a platform for
testing vaccine and drug candidates against active as well as
dormant Mtb potentially helping development of new and effective
drugs and vaccines against TB. This model can also be used to test
for anti-mycobacterial drugs that can kill dormant Mtb.
Materials and Methods
PBMC Cell Isolation from Human Blood
Human Blood was collected at a blood donation center of the
Florida Blood Center in Orlando, FL, from healthy volunteers as
per written informed consent. Florida Blood Centers operates
under license from the Food and Drug Administration of the US
Department of Health and Human Services. Blood collection and
processing was done as per approval from IRB which determined
that our use of blood from the Blood Center is exempt from our
institutional review board. All donors were tested negative for
standard panel of blood-borne pathogens tested by the blood
center. PBMCs were purified by Ficoll density gradient separation
using standard protocol used for separating PBMCs. After
washing, PBMCs aliquots of 26107 cells/vial were cryopreserved
in 10% DMSO-containing media for extended storage in liquid
nitrogen. When needed, PBMC vials were thawed and then
washed in RPMI containing 5% human Serum. Cells were
suspended in RPMI containing 20% human serum and counted
by trypan blue dye exclusion method.
Mtb Culture
M. tuberculosis H37Rv (WT) was cultured in Middlebrook 7H9
medium (supplemented with 10% OADC, 0.2% glycerol and
0.05% Tween 80) (Difco, USA) Dtgs1 [63] and DlipY [62] mutants
were cultured in the same medium with Hygromycin 75 mg/ml.
Dtgs1 C+and DlipY C+, were cultured in the same medium with
Hygromycin 75 mg/ml and kanamycin 20 mg/ml. Cultures
containing 2.86108 cfu/ml Mtb was used for all experiments.
Mtb cells were suspended in 1 ml of RPMI containing 20% human
Serum, water bath-sonicated for 2 pulses of 30 s each and used for
infection.
PBMC Infection and Granuloma Formation
An extracellular matrix (ECM) was prepared by mixing 0.95 ml
Purecol collagen solution, 50 ml 106DPBS (Lonza, USA), 4 ml
fibronectin (BD Biosciences, USA) and 10 ml 1N NaOH (Sigma,
USA) per ml of matrix solution and kept on ice (pH 7.0 ). PBMC
cells were mixed at room temperature (RT) with ECM at
56105cells/50 ml/well of 96-well plate. Assuming 5% macro-
phages in PBMCs, required strain of Mtb was added to the ECM
for infected samples at MOI of 0.1. ECM was allowed to set by
incubating on 37uC, CO2 incubator for 45min. Samples were
added with RPMI containing 20% human Serum and incubated
in 37uC, CO2 incubator. Media was changed on day7.
Paraffin Embedding, Sectioning and Histological Staining
On day 8 or 9 of incubation, media was removed from
granuloma samples and fixed with 4% paraformaldehyde over-
night. Samples carefully removed intact from the wells were
paraffin-embedded and sectioned, [65] Paraffin sections were
deparaffinized and stained by standard acid-fast bacilli (AFB)
staining or by Auramine O-Nile Red fluorescent staining. For AFB
staining, slides were stained using TB quick stain kit (Becton
Dickinson Biosciences, USA) using manufacturer’s protocol.
Immunohistochemistry for Cell Types in the in vitro
Granuloma
For immunohistochemistry 0.5 micron meter sections were
subjected to immunohistochemistry [65]. Deparaffinized sections
were boiled in 10 mM Citrate buffer for 30 min, cooled, and
blocked with 5% normal donkey serum in PBST for 40 min.
incubated with CD3(Tcell marker) polyclonal rabbit anti-human
antibody from Dako overnight. followed by incubation with
fluorescent secondary antibody Dylight 488 conjugated affinipure
donkey anti-rabbit IgG (green) for 30 minutes, then incubated with
CD68 Mouse Monoclonal antibody (macrophage marker) for
60 min. and finally incubated with fluorescent secondary antibody
CY3 conjugated affinipure donkey anti-mouse IgG (Red) for
30 min. After washing and dehydrating the slides were mounted
with media containing DAPI, and viewed under a Nikon TE2000
florescent microscope (Nikon Corp., Tokyo, Japan). Images were
acquired using a coolsnap HQ2 camera (Photometrics, Tusco-
n,AZ) or a Nikon Digital Sight DS Ri1 camera. ‘‘NIS elements’’
software (Nikon) was used for acquisition of images. Images were
taken using the Texas red filter set, FITC filter set and the DAPI
filter set (Chroma, Rockingham,VT).
AuramineO-Nile Red Staining
Staining was done using TB Fluorescent Stain Kit M (Becton
Dickinson Biosciences, USA), as described [36,40]. Slides were
mounted in cytoseal with coverslip and viewed under the Nikon
TE2000 florescent microscope (Nikon Corp., Tokyo, Japan).
Images were acquired using a cool snap HQ2 camera (Photomet-
ric, Tuscon, AZ) or a Nikon Digital Sight DS Ri1 camera. ‘‘NIS
elements’’ software (Nikon) was used for acquisition of images.
Images were taken using the Texas red filter set, and the FITC
filter set (Chroma, Rockingham, VT).
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Rifampicin Treatment and Plating
Rif was dissolved in DMSO, and granuloma samples were
either treated with Rif or left untreated (control) (Sigma, USA)
(Rif, 5 mg/ml final concentration). Earlier works from our lab have
used this concentration of Rif. On day 8- or 9-post-infection,
media was removed, replaced with 100 ul/well of media contain-
ing Rif and incubated for 3 days. Then, media was removed and
wells treated with 50 ml/well collagenase (Sigma, USA) for 40 min
at 37uC to isolate host PBMC cells. Samples from five wells were
pooled in 1.8 ml micro centrifuge tubes and host cells were lyzed
with 200 ml of 0.1% triton X-100 solution.Mtb pellet was obtained
by centrifuging at 35006g for 12 min. the Mtb pellet was
suspended in 1 ml 7H9 media and 10-fold serial dilutions were
made in Middlebrooks 7H9 media containing 0.05% tween-80
and 100 ml samples plated on Middlebrooks 7H10 agar plates.
Plates were incubated at 37uC. Colony forming units (cfu) were
determined after four weeks. % Rifampicin-tolerance is calculated
by formula - %Rif-tolerance = cfu(Rif)/cfu(untreated)6100.
Apoptosis Assay
Nuclear DNA fragmentation consistent with apoptosis was
determined by the TUNEL method [66,67]. We used the
CFTM594 TUNEL Assay Apoptosis detection kit. (Biotium).
TdT catalyzed the addition of dUTP conjugated to red fluorescent
dye, onto the 38-OH termini in the DNA of apoptotic cells. DAPI
blue counterstain was also used. Media was removed from the
wells containing uninfected PBMCs and IgG or anti-TNFa mAB
treated granulomas, and they were treated with 50 ml/well
collagenase (Sigma, USA) for 40 min at 37uC to isolate host
PBMC cells. Samples from five wells were pooled in 1.8 ml micro
centrifuge tubes and cells were fixed with 4% paraformaldehyde
overnight. A smear of fixed cells was put onto the slide, and were
then microwaved for 2 min in 10 mM Citrate buffer. The slides
were washed with PBS twice, and then permeabilized in PBS
containing 0.2% Triton X-100 for 30 minutes. TUNEL assay was
done following the kit protocol. The slides were then mounted
with mounting media containing DAPI. Slides were then observed
using a Nikon TE2000 florescent microscope (Nikon Corp.,
Tokyo, Japan). Images were acquired using a cool snap HQ2
camera (Photometric, Tuscon, AZ) or a Nikon Digital Sight DS
Ri1 camera. ‘‘NIS elements’’ software (Nikon) was used for
acquisition of images. Nuclei containing dark red precipitate
indicated TUNEL-positive cells. Five to six random fields totaling
500 cells were counted per slide. The percentage of cells
undergoing apoptosis is calculated by dividing the number of
positive nuclei by the total number of nuclei counted multiplied by
100.
Bioplex Cytokine Assay
Cytokine/chemokine analysis from granuloma supernatants was
done using 22-plex Beadlyte human cytokine/chemokine kit
(Millipore, USA) as per manufacturer’s instructions.
Flow Cytometric Analysis
Host cells were isolated by collagenase treatment of granuloma
and uninfected samples as described above. Cells from five similar
wells were pooled and washed with 1x PBS. Surface and
intracellular staining was done in a seven-color analysis with
combinations of fluorescein isothiocyanate (FITC)-, phycoerythrin
(PE)-, allophycocyanin (APC)-, peridinum chlorophyll Cy5.5
(PerCP-Cy5.5)-, phycoerythrin Cy7 (PE-Cy7)-, allophycocyanin
Cy7 (APC-Cy7)-conjugated antibodies and Annexin V-Pacific
Blue. Antibodies used included: anti-CD3 (clone SK7), anti-CD4
(SK3), anti-CD8 (SK1), anti-CD11c (B-ly6), anti-CD19 (HIB19),
anti- CD25 (2A3), (Becton Dickinson Biosciences, USA). Flow
cytometric data was analyzed using FloJo software (Becton
Dickinson, USA).
Treatment of Granulomas with IgG or anti-TNFa
Monoclonal Antibody
After the formation of microgranuloma, anti-TNFa monoclonal
antibody or control IgG was added to the media at a concentration
of 10 ng/ml.
Metabolic Activity of Mtb Using Alamar Dye
After 6 days of treatment of granulomas with anti-TNFa
antibody or control IgG, the Mtb cells recovered as indicated
above were suspended in media and 100 ml were added to each
well of a black bottom microtitre plate. 10 ml of 1:1000 diluted
Alamar blue was added to each well and the increase in
fluorescence at 590 nm, after excitation at 530 nm, was monitored
at different time intervals after addition of the dye using a BioScan
Chameleon V plate reader. Wells containing 100 ml of media and
10 ml of 1:1000 diluted Alamar blue were used as a control. The
Alamar readouts were normalized with cfu counts for each strain
and analyzed.
Metabolism of Oleic and Palmitic Acid
The Mtb was obtained from PBMCs as described earlier. In
a test-tube the Mtb cells were suspended in1ml 7H9 media without
glycerol, and 5 mci of [1-14C] oleic acid or [1-14C] palmitic acid
was added to the cells. A thin strip of filter paper dipped in
20%KOH was carefully hung at the mouth of the test-tubes and
the tubes were then sealed tightly with rubber stoppers and kept on
rollers for 4 hr. After 4 hours, the filter paper was carefully
removed and submerged in scintillation fluid and the amount of
14CO2 was determined by liquid scintillation counting using a tri-
Carb 2900 liquid scintillation analyzer (Perkins-Elmer,
Waltham,M.A). The dpm was normalized to the cfu counts of
Mtb from IgG or anti-TNFa antibody treated granulomas and the
data is presented as pmoles of 14CO2 released.
Gene Expression Analyses of Mtb from in vitro
Granuloma – Infection, RNA Isolation, Multiplex Pre-
amplification PCR and TaqMan Real-time PCR
Infection of PBMC to induce granuloma formation was done as
described above in this section. After the required period of
incubation for granuloma formation and resuscitation media was
removed from each well. RLT buffer (RNeasy Kit from Qiagen
Inc., USA) containing bmercaptoethanol, and RNase inhibitor
was added to each well and incubated for less than 10 min at 37uC
to lyse the collagen matrix and release the granuloma and the Mtb
cells. The lysate was collected in a tube and centrifuged at 35006g
for 12 min. The pellet was resuspended in trizol and snap frozen
in liquid nitrogen. It was then stored until further use. RNA
isolation, cDNA synthesis, multiplex pre-amplification PCR and
TaqMan real-time PCR were performed as we have described
earlier [13,36].
Accession Numbers
tgs1/Rv3130c, POA650; lipY/Rv3097c, P77909.
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